Affiliation: Northumbria University

A significant focus of Stephany Veuger's research has been to evaluate DNA repair inhibitors as potential drugs to be used in combination with current therapies or as stand-alone therapies in cancer treatment. She has supported anticancer drug discovery projects by 

(1) evaluating drugs to exploit underlying molecular defects in a range of human cancers,

(2) investigating interactive effects of proteins involved in sensing and responding to DNA damage,

(3) developing and validating pharmacodynamic biomarkers for agents progressing to clinical trials.

She has played a vital role in the drug development group at the Northern Cancer Centre. Her work evaluating agents progressing to clinical trials and developing biomarkers contributed to the successful introduction of PARP inhibitors into patients. She is interested in solid tumors (breast and prostate) and hematological malignancies. She currently collaborates with medicinal chemists to explore the underlying biological mechanisms of novel therapeutics alone and in combination with repair inhibitors.